Health Economics›Non-small cell lung cancer›Metastatic disease all lines of therapy

Metastatic disease all lines of therapy

Non-small cell lung cancer · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pemetrexed, Pembrolizumab Variant #01	ERBB2	R 96 550	21d	~11.2 mo	—	~36	~R 3 351 004 PFS proxy · indirect	1
Cisplatin, Pemetrexed, Pembrolizumab Variant #01	ERBB2	R 95 653	21d	~11.2 mo	—	~35	~R 2 951 550 PFS proxy · indirect	1
Trastuzumab deruxtecan monotherapy Variant #01	ERBB2	R 81 019	21d	~15.5 mo	~22.9 mo	~2	~R 162 039 PFS proxy · indirect	11
Capmatinib monotherapy Variant #01 Partial	MET	—	28d	—	—	~2	—	—
Tepotinib monotherapy Variant #01 Partial	MET	—	28d	—	—	~2	—	—

5 of 5 regimens shown